Drugs / Bivalent Pfizer-BioNTech
last change Nov 2022 re-read 2 minutes ago

Bivalent Pfizer-BioNTech

also known as BNT162b2 OMI
Developed for
COVID-19

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT05543356 Comparator May → Jul 2022 COVID-19 Murdoch Childrens Research Institute Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Bivalent Pfizer-BioNTech ClinicalTrials.gov intervention name — accepted as the source's own label NCT05543356
Known as BNT162b2 OMI “Biological/Vaccine: Pfizer-BioNTech, BNT162b2 OMI - bivalent Pfizer-BioNTech bivalent COVID-19 vaccine contains ancestral BNT162b2 and Omicron variant BNT162b2 Omi (BA.1).” NCT05543356